期刊名称 Cancer Biology & Therapy
期刊缩写 CANCER BIOL THER
学科分类 医学、生命科学
出版周期 月刊
审稿速度 2.33 个月 （平均）
投稿命中率 50 % （均值)
期刊主页 http://www.landesbioscience.com/journals/cbt/
ISSN 号 (printed): 1538-4047 (electronic): 1555-8576
IF 趋势 2005 2006 2007 2008 2009 2010 2011 2012
2.981 2.818 2.873 2.761 2.711 2.907 2.636 3.287
被收录情况 1. Science Citation Index Expanded
PubSci评语 审稿速度还可以，编辑对中国作者比较友好，有很多来自中国的研究报道。需要版面费。关注肿瘤的生物学及治疗领域。
期刊简介 该刊主要关注癌症的分子基础研究以及与癌症的诊断和治疗相关的研究论文。
投稿注意事项 特别提醒：字数不限，但需要支付每页100美元的版面费。同时，印刷形式出版的彩页首页340美元，其后每页收取150美元。在线发表的彩页不计费。
一般注意事项：
Editorial Policies
When a manuscript is submitted, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission.
Upon acceptance, authors must sign a License to Publish. Should the authors choose to make their paper freely available, then an Open Access License Agreement must be signed and will replace the License to Publish (please see the Landes Bioscience Open Access Policy for further details).
Manuscripts should conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (URMSBJ), which can be found in full at www.icmje.org. This is in addition to their need to conform to our general guidelines about layout, etc. In particular, the attention of authors is drawn to the following conditions (which are extracted from the URMSBJ):
Authorship (Informed Consent)
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data or analysis and interpretation of data; 2) drafting the article or reviewing/revising it critically for important intellectual content and 3) final approval of the version to be published. Each author should meet all three of these criteria. Acquisition of funding, or general supervision of a research group, are not valid criteria for authorship. Individuals who have a lesser involvement should be thanked in the acknowledgements. If meeting these requirements causes problems for a particular manuscript, authors are encouraged to contact the Editor-in-Chief for advice on alternative ways other contributors can be listed.
Acknowledgment of Funding
Authors should list all sources of funding for the research described in a manuscript in the 'Acknowledgments' section.
Conflict of Interest
Potential conflicts of interest exist when an author or reviewer has financial or personal interests in a publication that might, in principle, influence their scientific judgment. Financial interests include, but are not limited to, stock-holding, consultancy, paid expert testimony and honoraria; they also include any limitations on freedom to publish that are imposed on an author by an employer or funding agency. In order to encourage transparency without impeding publication, authors are required to include a statement at the end of a manuscript that lists all potential financial interests or, if appropriate, that clearly states that there are none. Possible conflicts of interest of a personal nature should also be communicated to the Editor-in-Chief, who will discuss with the author whether these ought to be listed. Peer reviewers are also required to inform the Editor-in-Chief of any potential conflicts of interest, financial or otherwise.
Ethical Statements
If a study involves any ethical issues, which include patient confidentiality and treatment of animals, the paper must be accompanied by a statement to the effect that the authors complied with all of the legal requirements pertaining to the location(s) in which the work was done.
Indicate whether the procedures were approved by the Ethics Committee of Human Experimentation in your country, or are in accordance with the Helsinki Declaration of 1975.
Duplicate or redundant publication
We only publish original manuscripts that are not also published or going to be published elsewhere. Duplicate publications, or redundant publications (re-packaging in different words of data already published by the same authors) will be rejected. If detected after publication, the Editor reserves the right to publish a notice of the fact without requiring the authors' approval. Competing manuscripts on the same study, for example by collaborators who have split into rival teams after the data were gathered, are acceptable only under special circumstances: please contact the Editor-in-Chief for advice.
Plagiarism and other fraud
If the Editor has reason to suspect that a manuscript is plagiarized or fraudulent, he or she reserves the right to bring his concerns to the authors' sponsoring institution and any other relevant bodies.
Upon submission, all manuscripts go through a rigorous quality control check that includes evaluation byiThenticate to identify any previously published phrases. Authors should pay particular attention to the originality of their work.
Limits to freedom of expression
We are committed to academic freedom. It does, however, have to operate within the laws of the USA, where it is published. Although a liberal democracy that is committed to academic freedom, it does have certain legal restrictions on the publication of specific types of material (for example, defamation of character, incitement to racial hatred, material intended to aid terrorism, etc.). In the unlikely event that a manuscript contains material that contravenes these restrictions, the journal reserves the right to request that the material is removed from the manuscript or that the manuscript is withdrawn. In any case, the journal requires authors to take full legal responsibility for what they have written.
iThenticate
Landes Bioscience uses iThenticate to screen for plagiarism before publication. The iThenticate software checks submissions against millions of published research papers, documents on the web, and other relevant sources. Authors, researchers and freelancers can also use the iThenticate system to screen their work before submission by visiting iThenticate.
Availability of Materials and Data
It is expected that authors should be able to provide any materials and/or protocols used in published experiments to other qualified researchers for their own use. Materials include (but are not limited to): cells DNA, antibodies, reagents, organisms, mouse strains, and Drosophila strains. These should be made available in a timely manner and it is acceptable to request reasonable payment to cover the cost of maintenance and transport.
For materials such as mutant strains and cell lines, authors should use established public repositories and provide relevant accession numbers wherever possible.
Repositories include:
Jackson Laboratory (mouse strains)
Bloomington Drosophila Stock Center at Indiana University (fly strains)
Drosophila Genomics Resource Center (DNA clones and cell lines)
MMRRC (Mutant Mouse Regional Resource Centers)
UK Stem Cell Bank
Papers reporting protein or DNA sequences and molecular structures should provide an accession number to any of the three major collaborative databases: DDBJ, EMBL or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL and GenBank on a daily basis. The suggested wording for referring to accession-number information is: 'These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345.'
Peer Review
Each contribution is typically vetted by at least two expert reviewers who are either members of the Editorial Board or are recruited by Board members.
For original articles or short reports, reviewers will generally be asked to comment on the following aspects of the submitted manuscripts:
significance to the field
study of data
quality of data
quality of controls
whether conclusions are justified
whether the effects are meaningful
whether the study is described clearly
the novelty of the work
If the reviewers believe the paper is potentially acceptable, but could be improved, specific suggestions will be made for improvement.
Final acceptance of all submitted manuscripts is a decision made by the Editor(s) in consultation with the Editorial Board and reviewers. If a manuscript does not meet the standards of the journal or is otherwise lacking in scientific rigor or contains major deficiencies, the reviewers will attempt to provide constructive criticism to assist the authors in ultimately improving their work for publication, here or elsewhere. Manuscripts not invited for resubmission will not be reconsidered.
If a manuscript receives favorable reviews but is not accepted outright following the initial review, it may be invited for reconsideration with the expectation that the authors will fully address the reviewer’s criticisms. Resubmitted manuscripts with major revisions will be sent back for peer review.
If an author wishes to appeal an Editorial decision, please contact Kimberly Mitchell, Journal Publications Director.
Accepted papers will be rapidly posted to the journal website as an E-publication (ahead of print).
Author Self-Archiving
Authors are entitled to deposit a final version of their manuscript in their institution's repository immediately upon publication. Again, we only require that a link to the published version at the journal's website is included, along with attribution to the journal as the original source (with full citation details).
Corrections and Retractions
All formal notices of correction, retraction, and expressions of concern are published as separate article entries that contain citation information and/or directly link back to the original publication to which they apply. They are automatically designated as readily available online to the public without charge. If a title is published in print, the notification will also be included in the corresponding print version of a journal.
Landes Bioscience strives to follow the standards and guidelines set by the International Committee of Medical Journal Editors (ICMJE).
Corrections
Corrections should be brought to the attention of the Managing Editor and/or Editor-in-Chief of the specific journal title for resolution. Significant errors that may impact the understanding of the science or incorrect elements that may effect the citation of the publication (i.e., misspelling of an author’s name) are grounds for formal correction. These include significant errors resulting from mistakes introduced by publishing staff during the production and editing process of an article or notification of errors in scientific logic, methodology and/or omissions by authorship. Note, a formal correction will not be published for basic grammatical or typographical errors.
Retractions and Expressions of Concern
If the integrity of a publication is brought into question, concerns should be brought to the attention of the Editor-in-Chief.
In the unlikely event that potential error in scientific logic or methodology invalidates the results of an entire body of work, a partial or full retraction of the article, may be published. In these instances, were authors voluntarily elect to retract their own work, circumstances are addressed between the authorship and Editor-in-Chief.
Retraction of an article may also be issued on confirmed instances of scientific fraud related to plagiarism, fraudulent data usage, invalid claims of authorship, or breaches in professional codes of ethics. If the grounds for retraction are confirmed by the author(s) institution(s) or funding agency related to the work, a formal retraction will be published. If an investigation into scientific fraud does not reach a satisfactory conclusion and validity remains uncertain or if the investigation appears to be drawn out over an extended period of time (without a foreseen date of closure), an “Expression of Concern” regarding the validity of the original publication may be published.
General reader feedback and criticisms
Readers are encouraged to submit feedback to the Editor-in-Chief that supports,challenges, and/or elaborates upon previous publications. The Editor-in-Chief may consult with the original authorship of a publication or seek the advice of peer-reviewers to determine an appropriate response in cases where significant errors are noted.
If the feedback is of significant interest, it may be considered for publication as a “Letter to the Editor” at the discretion of the Editor-in-Chief. In these cases, the original authorship of a publication may be given the chance to respond to the feedback in a published “Reply to” or “Response to” article.
Open Access Policy
Landes Bioscience recognizes that an increasing number of research-funding agencies require agency-funded research be deposited in public repositories. It is our mission to help authors comply with their institutions and funding agencies.
Landes Bioscience Open Access License Agreement
Once a manuscript has been accepted for publication, authors may let the Managing Editor know that they wish to purchase open access for their paper. Otherwise, all authors will receive an order form with their galley proofs.
Open Access prices vary based on the type of paper and the desired Creative Commons license you wish to use. A description of the licenses that we work with is here:
CC-BY-NC: Anyone may copy, distribute, transmit, or adapt the work as long as the work is attributed (properly cited). This work may not be used for commercial purposes.
CC-BY: Anyone may copy, distribute, transmit, adapt, or use the work for commercial purposes as long as the work is attributed (properly cited).
Open Access
Type of Paper
Fee
CC-BY-NC license
Report
$750
Short Report
$500
Review
$500
Commentary
$250
CC-BY license
Report
$1,500
Short Report
$1,000
Review
$1,000
Commentary
$500
Landes Bioscience Open Access Agreement for CC-BY-NC
Creative Commons Attribution Noncommercial License
Creative Commons Attribution Noncommercial License – Full Legal Code
Landes Bioscience Open Access Agreement for CC-BY
Creative Commons Attribution License
Creative Commons Attribution License – Full Legal Code
Compliance with Funding Agencies
All manuscripts that are agency-funded (e.g., NIH, HHMI, Wellcome Trust, etc.) and paid for using one of the above Creative Commons licenses will be automatically deposited and made publicly available in PubMed Central by the publisher. Agency-funded articles that are not open access will be deposited by the publisher and publicly available in PubMed Central (and Europe PMC) within 6-12 months of publication. Please note that Wellcome Trust-funded authors selecting an OA option are required by their funder to select the CC-BY license.
Author Self-Archiving
Authors are entitled to deposit a final version of their manuscript in their institution's repository immediately upon publication. Again, we only require that a link to the published version at the journal's website is included, along with attribution to the journal as the original source (with full citation details).
Manuscript Submission
Online Submission
Cancer Biology & Therapy utilizes an online submission and tracking system designed to provide a better, more efficient service to authors.
Authors can submit manuscripts online from anywhere in the world.
Authors can track their manuscript through the peer review process.
Author files are automatically converted into a PDF (Portable Document Format) file and submissions are acknowledged by email.
Editors and reviewers access the PDF files on the website.
Click here to submit your manuscript to Cancer Biology & Therapy.
Previously Submitted
Cancer Biology & Therapy recognizes that excellent papers may have been erroneously rejected by other journals. We will reconsider papers that have been rejected by Nature, Science, Nature Medicine, Nature Cell Biology, Cell, Cancer Cell, Cell Metabolism, Developmental Cell, NEJM, Lancet, Genes & Development and some other journals in the original format of those journals, thus saving the authors effort and time. Authors are encouraged to enclose the reviewers' and/or editorial comments from the journals mentioned above. This will expedite the evaluation of the article. In some instances, the article may be accepted based on the previous review. This allows urgent and competitive research to be published soon after submission. Papers submitted using the Select Submission Track can be accepted within 1-2 days.
Please submit your paper and contact the Editor-in-Chief with the manuscript number and a PDF with the previous review. Upon acceptance, authors should provide the paper in Cancer Biology & Therapy's format.
Pathway 2 for Manuscript Submission
Authors may also submit a manuscript to Cancer Biology & Therapy requesting that a specific Associate Editor oversee the review for consideration by the journal. If an author chooses this mechanism, the following conditions apply:
The senior author will have previously contacted the Associate Editor and obtained their agreement to oversee the review of the manuscript.
The manuscript is in the area of expertise of the Associate Editor.
Copies of the manuscript are otherwise submitted to the journal using the required normal procedure, with correspondence to the Editor-in-Chief explaining what is being done. This is important for tracking manuscripts under review and helps to prevent overburdening Associate Editors with too many manuscripts. In such situations, a manuscript may be sent to others for review.
The final decision regarding manuscript acceptance will be made by the Editor-in-Chief, in consultation with the Associate Editor, following review of the manuscript.
The journal reserves the right to obtain additional reviews for any manuscript under consideration.
When your paper is accepted and proofs are sent, you will be given two days to return your corrections. If we do not receive your corrections within the given time frame, we will post an uncorrected proof online. The uncorrected proof will remain online until your corrections are received.
Pre-submission Inquiries
Pre-submission inquiries are not necessary but are welcome. These may include either an abstract or a full-length manuscript as an email attachment (Microsoft Word). Pre-submission inquiries should be emailed to the Editor-in-Chief (Wafik S. El-Deiry).
Non-Native Speakers of English
Authors who are not native speakers of English and submit manuscripts to international journals, often receive negative comments from referees or editors about English-language usage. These problems can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors to take at least one or both of the following steps:
Have your manuscript reviewed for clarity by a colleague whose native language is English.
Use a service such as one of those listed at the end of our guidelines. An editor will improve the English to ensure that your meaning is clear and identify problems that require your review. Note that the use of such a service is at the author's own expense and risk, and does not guarantee that the article will be accepted. Landes Bioscience accepts no responsibility for the interaction between the author and the service provider or for the quality of the work performed.
Manuscript Preparation
Types of Papers
Letter to the Editor
A short, focused text with references, addressing a specific publication in Cancer Biology & Therapy. Before such a Letter is published, the author of the original published article will be given the opportunity to reply to the Letter. If the author wishes to reply, the Letter and Reply Letter will be published together in the same issue of the journal.
Reviews
Reviews should be recognized as scholarly by specialists in the field being covered, but should also be written with a view to informing readers who are not specialized in that particular field, and should therefore be presented using simple prose. Please avoid excessive jargon and technical detail. Reviews should capture the broad developments and implications of recent work. The opening paragraph should make clear the general thrust of the review and provide a clear sense of why the review is now particularly appropriate. The concluding paragraph should provide the reader with an idea of how the field may develop or future problems to overcome, but should not summarize the article. To ensure that a review is likely to be accessible to as many readers as possible, it may be useful to ask a colleague from another discipline to read the review before submitting it. Submitted reviews are subject to the same page charges as full-length reports—whether and how page charges will apply for commissioned reviews will be determined upon each commission. Reviews should include an abstract of 150 words and should cite no more than 150 references. Please include 5-10 key words for indexing purposes.
Focused Review Series
The Editors of Cancer Biology & Therapy invite members of the scientific community to consider topics of interest to our readers and to organize small series of focused reviews in particular areas. This will involve proposing a topic of interest, contacting potential authors for 2-4 or more reviews and providing the titles of the reviews, the names of the authors, and when they would be ready. Cancer Biology & Therapy aims to publish outstanding reviews by accomplished authors. In writing reviews, please note that we are most interested in content and that there is flexibility in word count, number of references or number of figures. Please contact the Editor-in-Chief if you are interested in organizing a Focused Review Series.
Meeting Reports
Meeting Reports are summaries of presentations from recent meetings in the field. Authors are encouraged to contact the Editor-in-Chief with proposals for meeting reports. Also, please contact the meeting organizers to verify that reports will be permitted. Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Journal Club
Journal Club articles include descriptions and critiques of major advances published in other leading journals. It is modeled after, and driven by, journal club presentations held in most institutions around the country and would be a good opportunity for students of all ages (faculty, post-docs, and graduate students) to share their critiques with a wider audience. This is, therefore, an open invitation to suggest specific papers to be featured and critiqued. We look forward to your participation in the Journal Club.
Bedside-to-Bench Reports
These consist of one or more case reports, followed by a thorough and up-to-date discussion of the molecular biology of the disease. These reports should include an abstract, a brief introduction and a clinical case report, followed by a discussion of Clinical Features, Pathology, Radiology, Therapy, and Molecular Features. The total report should be kept under 4,000 words, and the Molecular Features should comprise about one-half to two-thirds of the report. The goal of this section is to provide clinicians with a perspecive of the molecular aspects, and the basic scientists with a perspective of the clinical aspects. This represents one format through which CB&T will impart translational knowledge.
Research Philosophy and Profiles & Legacies
For Profiles and Legacies, the Editors of Cancer Biology & Therapy invite prominent scientists and clinicians to write about their careers and experiences; in addition, their photo is published on the cover. Each article in the Profiles and Legacies section contains the subsection "Biographical Information," detailing briefly the person's career path. The main text section can carry any subtitle(s) they choose, or could simply be "Philosophical Views." Often, there is also a section entitled "Vision of the Future," where they comment and advise on the future direction of cancer research. Each Profile we have published has been very interesting for our readership in part because of the unique experiences and perspectives provided.
The Editors invite groups of authors to pay tribute to outstanding individuals who have had a major impact on the field of cancer research. We also invite submissions featuring new centers or major expansions at well-established institutions (new institutes or centers). This is a great way to share the excitement and attract attention to what's happening.
Articles in the Research Philosophy section can be submitted by authors without prior invitation. These articles discuss general areas of scientific philosophy or more specialized areas, such as post-doctoral training, career development of trainees, grantsmanship, scientific style, and decision-making at crossroads in research, just to name a few. We are interested in a variety of additional topics including experiences in discovery and scientific progress, views or advice to scientists of all ages, the impact of genomics, translational research, proteomics, as well as any insights into careers in industry, academia, or careers of physician scientists.
Research Papers/Reports
Research Papers or Reports should include the following sections in the following order:
Abstract: A single paragraph of fewer than 250 words. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. References should not be cited in the abstract.
Keywords: Include 5-10 for indexing purposes.
Introduction.
Results: Present results in a logical sequence in tables and illustrations. In the text, explain, emphasize or summarize the most important observations. Units of measurement should be expressed in accordance with Systeme International d'Unites (SI Units).
Discussion: Do not repeat in detail data given in the Results section. Emphasize the new and important aspects of the study. Relate observations to other relevant studies. On the basis of your findings (and others'), discuss possible implications/conclusions. When stating a new hypothesis, clearly label it as such.
Patients and Methods/Materials and Methods: Describe the selection of patients or experimental animals, including controls. Do not use patients' names or hospital numbers. Identify methods, apparatus (manufacturer's name and address) and procedures in sufficient detail to allow other workers to reproduce the results. Provide references and brief descriptions of methods that have been published. When using new methods, evaluate their advantages and limitations. Identify drugs and chemicals, including generic name, dosage and route(s) of administration.
Indicate whether the procedures were approved by the Ethics Committee of Human Experimentation in your country, or are in accordance with the Helsinki Declaration of 1975.
For reagents listed in the Materials and Methods section, the company that supplied the reagent and the catalog number should be listed in parentheses; do not list the company location.
References: No more than 85.
Figure legends.
Tables: Tables should be numbered consecutively with Arabic numerals and include descriptive titles and legends.
Commentaries
Commentaries (reviews of manuscripts published in Cancer Biology & Therapy) will be invited by the Editor-in-Chief or the Scientific Managing Editor. The purpose of the commentary is to put a paper appearing in a current issue of Cancer Biology & Therapy into context for scientists who are not necessarily familiar with the field under discussion. As such, it should have some relevant background information, comments on the paper, areas that need further investigation and future directions. Authors are encouraged to include a figure to explain the significance of the pathway being discussed and its relationship to cancer. In order to provide authors enough space to provide a thoughtful commentary, there is no word limit, although most commentaries are 1-2 printed pages (approx. 1,500 words ). Please be sure to include the manuscript that you are commenting on in the references. Format the reference in the same manner as the rest of your references with X:XXX for the volume and page numbers. We will fill in the missing information when the issue has been paginated. Commentary authors are given 2-3 weeks to complete the review. Upon acceptance of the invitation to write a commentary, authors will receive an email from Cancer Biology & Therapy with a manuscript number and information about submitting the commentary online. Be sure to include 5-7 key words and a running title but please note that no abstract will be published for the commentary.
Organization
All manuscripts should be in English. Please ensure that manuscripts are clear, concise and grammatically correct.
Text should be prepared in MS Word, double-spaced, with page numbers throughout and line numbering turned on. Click here for directions on adding line numbers.
Organize manuscripts in the following manner:
Title page, including titles, author's names (first, MI, last) and affiliations
5-10 keywords (for indexing purposes)
A list of abbreviations and acronyms used throughout the text
An abstract (please see Type of Paper for word limit), the primary goal of which is to make the general significance and conceptual advance of the work clearly accessible to a broad readership. (References should not be cited in the abstract.)
Text (length and organization depends upon type of paper)
Acknowledgments
References
Figure legends
Tables (with descriptive titles and legends)
There are no word limits for papers published, however, accepted manuscripts are published with the understanding that page and color charges will be assessed. Please see the section, Page and Color Charges below.
If your paper is to be published in a journal indexed by PubMed/Medline, the citation of your article will be sent to PubMed within one week of acceptance; therefore, please ensure that all information is correct.
Text Files/Tables
Please save text and table files as MS Word documents. Figure legends should be at the end of the manuscript following references. Tables will be reformatted during production and therefore should only be minimally formatted in your text file and follow the figure legends.
Figure Preparation
Figures should be as small and simple as clarity permits. Unnecessary figures and panels in figures should be avoided: data presented in small tables or histograms, for instance, can generally be stated briefly in the text instead. Avoid unnecessary complexity, coloring and excessive detail. Figures should not contain more than one panel unless the parts are logically connected. Where possible, text, including keys to symbols, should be provided in the text of the figure legend rather than on the figure itself. Any image processing should be explained clearly in the Materials and Methods section of your manuscript.
To aid in the processing and turnaround of issues, we ask that authors please adhere to the following figure guidelines. Authors will be asked to revise details and images if they do not adhere to the figure protocols.
Guidelines for Figure Preparation
Image presentation
(These guidelines for image presentation are adapted from the “Instructions for Authors” that are posted on the Journal of Cell Biology web site, and are included here with permission).
As you prepare your figures, please adhere to the following guidelines to accurately present your data:
No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
The grouping of images from different parts of the same gel, or from different gels, fields, or exposures must be made explicit by the arrangement of the figure (i.e., using dividing lines) and in the text of the figure legend.
Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image and as long as they do not obscure, eliminate, or misrepresent any information present in the original, including the background. Non-linear adjustments must be disclosed in the figure legend.
A more detailed discussion of image presentation can be found at the following URL:http://jcb.rupress.org/content/166/1/11.full (Rossner and Yamada, J. Cell Biol. 166:11–15)
Resolution
All submitted images must be of high quality and have resolutions of 300 dpi ready for print.
Formats
We require figures in electronic format. Please do not send PowerPoint, MS Word, presentation or paint files as they are inadequate for the creation of high quality images. Much of the information contained in PowerPoint or other file types is lost or skewed in the conversion of images. Figures should be provided as TIF, Photoshop, EPS or high resolution PDF files. Compatible graphic art programs are Adobe Illustrator and Adobe Photoshop.
Figure size
Figures should be submitted at the size they are to be published. Maximum width = 7.1 in. Maximum height = 9.5 in.
For multi-panel figures (such as figure 1a, 1b, 1c, etc.), each panel should be assembled into one image file. Do not include separate panels on multiple pages, i.e. A, B, C and D should all fit on one page. Each panel should be sized so that the figure as a whole can be reduced by the same amount and reproduced on the printed page at the smallest size at which essential details, including type, are visible and readable.
Color mode
Save all color figures in CMYK mode at 8 bits/channel. Layering type directly over shaded or textured areas and using reversed type (white lettering on a colored background) should be avoided.
Type
Please be sure to embed all fonts. Use a sans serif font such as Helvetica. The font size should be no greater than 9 pt. and no smaller than 6 pt; however, panel labels (A, B, C) should be 15 pt. uppercase (not bold). Lettering in figures (labeling of axes and so on) should be in lowercase type, with the first letter capitalized and no full stop. Please keep font size relatively the same throughout the figures so as to avoid scaling issues. Also note that readability suffers if type is layered over a pattern or color other than white or black.
Units
Units should have a single space between the number and the unit, and follow SI nomenclature or the nomenclature common to a particular field. Thousands should be separated by commas (1,000). Unusual units or abbreviations should be defined in the legend. Please use the proper microsymbol (denoting a factor of one millionth) rather than a lower case u.
References
Include in the reference list only those articles that have been published or have been accepted for publication. All references to unpublished data or personal communications must be cited within the text.
Use the citation-sequence system: The list of references should be numbered consecutively according to the sequence of first appearance within the article text. For in-text references, use only the number assigned to the reference:
Correct: according to Jones.1
Incorrect: according to Jones1.
Correct: noted by Smith et al.1
Incorrect: Smith et al (1).
When referring the reader to specific references as part of a sentence please use the following format:
Correct: For a review see refs. 20-25.
Incorrect: For a review see 20-25
Journal References
The reference format is the same for all of our journals. You may download the output style for Cell Cyclefrom Endnotes, or view it in the CSL Style Repository.
List, at minimum, ten author names before using “et al.”
Abbreviate journal names according to the style used in Index Medicus or a comparable source and omit punctuation after journal titles. Spell out foreign or less commonly known journal names.
Standard format:
[Author's last name] [Author's initials], [First ten author's last names followed by their initials]. [Title of article with only the first word capitalized]. [Journal's standard abbreviated name] [Year]; [Volume]:[Inclusive pages].
For Example:
Haegel H, Thioudellet C, Hallet R, Geist M, Menguy T, Le Pogam F, Marchand J, Toh M, Duong V, Calcei A, et al. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells. mAbs 2013; 5: 243–56.
Other Types of References
For all other types of reference styling formats, please refer to the National Library of Medicine Style Guide for Authors, Editors and Publishers which is available here: http://www.ncbi.nlm.nih.gov/books/NBK7256
Supplementary Files
The following fees apply for any supplementary material posted with a manuscript. A $100 fee is assessed for all text, figures and/or tables. Supplementary movies carry a rate of $150 for the first five movie files and $50 for each subsequent movie file. Fees will be outlined on the publication charge form authors receive with galley proofs.
Please provide supplementary material in the following formats:
Text: MS Word file
Table/Data: MS Word file or Excel file
Figures: Please provide figures in a MS Word file or in a PPT file, clearly labeled with figure legends below them.
Video Files: Video submissions for viewing online should be Audio Video Interleave (.avi), MPEG (.mpg), or Quick Time (.qt, .mov).
AVI files can be displayed via Windows Media Player; MPEG files can be displayed via Windows Media Player; Quick Time files require Quick Time software (free) from Apple
Videos should be brief whenever possible (<2-5 minutes). Longer videos will require longer download times and may have difficulty playing online. Videos should be restricted to the most critical aspects of your research. A longer procedure can be restructured as several shorter videos and submitted in that form.
It is advisable to compress files to use as little bandwidth as possible and to avoid overly long download times. Video files should be no larger than 5 megabytes. This is a suggested maximum. If files are larger, please contact the Managing Editor.
A caption giving a brief overall description of the video content should be provided for each video.
If your paper is accepted for publication you may wish to supply the editorial office with several different resolutions of your video files. This will allow viewers with slower connections to download a lower resolution version of your video.
Please also provide ALL files in one PDF file. Links to supplementary data will be included in the PDF of the published manuscript and in the online abstract.
Cover Image Submission
Cancer Biology & Therapy selects a cover illustration from accepted articles, or from submitted images that are designed to accompany an accepted article.
The cover illustration should be scientifically interesting and visually attractive. The illustration need not be a figure from the paper, but should be closely related to the subject of the paper. If you are interested in submitting a figure for use as the cover of Cancer Biology & Therapy, please email a high-resolution version of your image, conforming to the specifications below, and an explanatory caption of 50-60 words to theManaging Editor.
All potential cover images should be sized to fit on a single letter size (8.5" x 11") page. Please remove all text, captions, etc. from the image. If you have variations of the image, you may send additional files. Please send no more than two alternate versions.
Accepted formats and resolution:
PSD (Adobe Photoshop: if graphics are built with layers, do not flatten), 300 dpi, CMYK at 100% size.
TIF, 300 dpi, CMYK at 100% size
JPG, 300 dpi highest quality, CMYK at 100% size.
EPS (scalable vector line art)
AI (Adobe Illustrator)
Publication Charges, Page Proofs and Ordering Reprints
Page Charges
Page charges apply at a rate of $100 per page or partial page used for articles classified as Reports, Research Papers, Technical Papers, Brief Reports and Short Communications.
Color Charges
Color charges are assessed separately from page charges and will be added to the total amount of page charges assessed. Publication of color images is free for the online
